Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Macular Pigmentation Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Antioxidants on Human Macular Pigments

NCT00718653
View directory record Official record
Conditions
Eye Health
Interventions
Lutein, Lutein plus green tea extract
Dietary Supplement
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2009 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Raman Scattering Spectroscopy to Measure Macular Pigment

NCT00060580
View directory record Official record
Conditions
Raman Spectroscopy
Interventions
Raman scattering spectroscopy
Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel)

NCT01354093
View directory record Official record
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
zeaxanthin
Drug
Lead sponsor
Paul S. Bernstein
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Jul 22, 2026, 4:56 PM EDT
Not listed Phase 1Phase 2 Interventional

Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD

NCT02590692
View directory record Official record
Conditions
Dry Macular Degeneration, Geographic Atrophy
Interventions
CPCB-RPE1
Biological
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Jul 22, 2026, 4:56 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

NCT07680244
View directory record Official record
Conditions
Epiretinal Membrane, Dry Age Related Macular Degeneration, Macular Abnormalities, Retina Disease, Vitreoretinal Abnormality, Intraretinal Hyporeflective Space, Subretinal Hyporeflective Space, IS/OS (Ellipsoid Zone) Disruption, Retinal Pigment Epithelium (RPE) Elevation, Retinal Pigment Epithelium (RPE) Atrophy
Interventions
PathFinder 1.0 on CIRRUS HD-OCT
Device
Lead sponsor
Carl Zeiss Meditec-Dublin CoCe
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Tucson, Arizona • Mountain View, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60

NCT00121589
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lutein
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

iSONEP to Treat Persistent Pigment Epithelial Detachment (PED) in Subjects With Exudative Age-Related Macular Degeneration (AMD) or Polypoidal Choroidal Vasculopathy (PCV)

NCT01334255
View directory record Official record
Conditions
Pigment Epithelial Detachment
Interventions
iSONEP (sonepcizumab/LT1009)
Drug
Lead sponsor
Lpath, Inc.
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
5
States / cities
Winter Haven, Florida • West Mifflin, Pennsylvania • West Columbia, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Jul 22, 2026, 4:56 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Macular Pigment Measurements in Eye & Other Tissues

NCT03022773
View directory record Official record
Conditions
Macular Pigmentation, Skin Pigment
Interventions
Carotenoid measurements
Other
Lead sponsor
University of Utah
Other
Eligibility
7 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Influence of Eggs on Cognitive Performance

NCT06465888
View directory record Official record
Conditions
Cognitive Function
Interventions
egg whites, whole eggs, Omega-3 eggs, egg yolk
Other
Lead sponsor
Texas A&M University
Other
Eligibility
50 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2025 · Synced Jul 22, 2026, 4:56 PM EDT
Not listed Phase 4 Interventional

On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)

NCT01670162
View directory record Official record
Conditions
Age Related Macular Degeneration, Pigment Epithelial Detachment
Interventions
Aflibercept
Drug
Lead sponsor
Tennessee Retina
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

NCT01682382
View directory record Official record
Conditions
Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
60 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2Phase 3 Interventional

Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments

NCT00590694
View directory record Official record
Conditions
Age-related Macular Degeneration, Pigment Epithelial Detachment, Neovascular Macular Degeneration, Wet Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
Pacific Eye Associates
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Jul 22, 2026, 4:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

Measurement and Analysis of Macular Retinal Pigment Epithelium (RPE) Elevations With Cirrus HD-OCT vs. Color Fundus Photography

NCT01272063
View directory record Official record
Conditions
Drusen Stage Macular Degeneration
Interventions
Not listed
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
50 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Oakland, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

NCT01880788
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
30 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2015 · Synced Jul 22, 2026, 4:56 PM EDT